Table 1.
Statistical analysis of mean change from baseline in QTcF
Time, hour |
Mean change from baseline, msec ddQTcF |
Mean difference vs. placebo (90% CI), msec ddQTcF |
|||||
---|---|---|---|---|---|---|---|
FTR 1,200 mg q.d. (A) |
FTR 2,400 mg b.i.d. (B) |
MOX 400 mg (C) |
Placebo (D) |
FTR 1,200 mg q.d. (A–D) |
FTR 2,400 mg b.i.d. (B–D) |
MOX 400 mg (C–D) |
|
0.5 | –7.44 | –6.04 | –7.12 | –7.54 | 0.10 (–1.98, 2.18) | 1.50 (–0.63, 3.62) | 0.42 (–1.73, 2.58) |
1 | –7.25 | –6.15 | –4.82 | –7.76 | 0.51 (–1.57, 2.58) | 1.61 (–0.51, 3.73) | 2.95 (0.80, 5.10) |
2 | –6.78 | –6.90 | –1.93 | –10.62 | 3.84 (1.75, 5.93) | 3.72 (1.60, 5.84) | 8.69 (6.57, 10.82)a |
3 | –7.54 | –3.67 | 0.40 | –10.03 | 2.49 (0.40, 4.57) | 6.36 (4.23, 8.48) | 10.43 (8.32, 12.54)b |
4 | –3.37 | 1.64 | 3.30 | –7.03 | 3.66 (1.58, 5.75) | 8.67 (6.55, 10.79) | 10.33 (8.22, 12.44)c |
5 | –0.49 | 6.50 | 4.16 | –4.67 | 4.18 (2.11, 6.26) | 11.18 (9.05, 13.30) | 8.83 (6.72, 10.94) |
6 | –4.52 | 0.18 | –0.81 | –8.78 | 4.27 (2.19, 6.34) | 8.96 (6.84, 11.10) | 7.98 (5.87, 10.09) |
8 | –6.87 | –3.46 | –0.74 | –8.79 | 1.92 (–0.15, 3.40) | 5.33 (3.21, 7.46) | 8.05 (5.94, 10.17) |
10 | 0.76 | 1.51 | 5.78 | –3.18 | 3.94 (1.86, 6.01) | 4.69 (2.57, 6.81) | 8.96 (6.85, 11.07) |
11.5 | –5.31 | –3.88 | 1.83 | –6.92 | 1.61 (–0.48, 3.69) | 3.04 (0.92, 5.17) | 8.75 (6.64, 10.86) |
14 | –7.05 | –1.65 | 0.60 | –6.95 | –0.10 (–2.18, 1.972) | 5.30 (3.18, 7.43) | 7.55 (5.44, 9.66) |
15 | –3.84 | 4.45 | 1.49 | –4.15 | 0.30 (–1.78, 2.38) | 8.60 (6.47, 10.73) | 5.64 (3.52, 7.75) |
16 | –1.48 | 8.59 | 5.41 | –1.52 | 0.04 (–2.04, 2.12) | 10.10 (7.98, 12.23) | 6.92 (4.81, 9.03) |
22.25 | –3.18 | 0.16 | 2.73 | –3.46 | 0.29 (–1.79, 2.36) | 3.63 (1.51, 5.75) | 6.19 (4.08, 8.30) |
CI, confidence interval; ddQTcF, difference vs. placebo for change from baseline in Fridericia‐corrected QT interval; FTR, fostemsavir; MOX, moxifloxacin; QTcF, Fridericia‐corrected QT interval.
Multiplicity‐adjusted 90% CI for MOX: a(6.57; 10.82); b(7.70; 13.16); c(7.81; 12.84).